BGLC
BioNexus Gene Lab Corp
$2.03
+0.03 (+1.50%)
At close · Jul 2
Going-concern doubt
— cleared May 15, 2026
The latest filing states the doubt was alleviated.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon improving its operating results and maintaining adequate liquidity. Management believes that the Company’s existing cash balance, together with its positive working capital position, will provide sufficient liquidity to fund operations and meet its obligations as they become due for at least the next twelve months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$4.91M
Shares
2,417,314
Registered funds — mutual funds, ETFs and closed-end funds — whose latest Form N-PORT portfolio report holds this stock, matched by the stock's CUSIP. Each row is one fund position with its size, value and weight in that fund.
Funds holding BGLC
2 fund positions| Fund | Ticker | Balance | Value | % of Fund | Side | Reported | Open |
|---|---|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | — | 2,368 | $6,465 | 0.00% | Long | 2026-02-28 | |
| Blackstone Alternative Multi-Strategy Fund | — | 3 | $6 | 0.00% | Long | 2026-03-31 |
Showing 1–2 of 2 positions